Skip to main content

Schizophrenia & Psychotic Disorders

Successfully treating reduced motivation, or avolition, in patients with schizophrenia has a positive effect on other negative symptoms, according to a study published online in Schizophrenia Bulletin.
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
Long-term use of antipsychotics by patients with schizophrenia does not increase the risk of hospitalization for comorbid conditions—and is actually associated with substantially decreased mortality, according to a study in World Psychiatry.
Having a dog in the household during childhood may significantly decrease the risk of schizophrenia later in life, suggests a study published online in PLOS One.
Cognitive aging appears to occur more rapidly in people with psychotic disorders, compared with peers without such disorders, according to a study that followed 445 people for 2 decades after their first psychotic disorder hospitalization.

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive…

What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top